HOME >> BIOLOGY >> NEWS
Compound inhibits one critical pathway in breast cancer growth

COLUMBUS, Ohio A compound that suppresses the growth of cancer cells and is relatively non-toxic to normal cells may one day be useful for treating several types of cancer, researchers report in this week's Proceedings of the National Academy of Sciences.

Laboratory experiments in human breast cancer cells suggest that the compound inhibits the constant activation of a protein called Stat3 that is found in several different types of cancer, including cancer of the breast, lung, prostate, head and neck, skin, pancreas and ovaries as well as lymphoma and certain kinds of leukemia.

Stat3 is constantly activated in about 60 percent of breast tumors, said Jiayuh Lin, the study's lead author and an associate professor of pediatrics at Ohio State University.

All cells contain Stat3 protein, but in normal cells, Stat3 activities are only turned on temporarily. Researchers do know, however, that Stat3 is constantly turned on in certain tumor cells.

"The cancer cells we studied seem to depend on Stat3 for survival," said Lin. "When we blocked the chain of events that activate Stat3, the cancer cells died."

Lin is also a member of Ohio State's Comprehensive Cancer Center and an investigator in the Center for Childhood Cancer at Columbus Children's Research Institute. He co-authored the study with Shaomeng Wang, Hui Song and Renxiao Wang, all with the University of Michigan Comprehensive Cancer Center.

The researchers named the compound STA-21. They tested STA-21 after using a computer program to narrow down a list of potential compounds to a manageable number that they could physically test in the lab.

When the computer screening process ended, the researchers tested the 100 top compounds. They tested these compounds on human breast cancer cells in order to find which one best stopped the constant Stat3 activation. STA-21 appeared to be the best inhibitor of Stat3 activity.

"This compound showed a remarkab
'"/>

Contact: Jiayuh Lin
linj@ccri.net
614-355-2652
Ohio State University
7-Mar-2005


Page: 1 2

Related biology news :

1. Scripps research scientists: Compounds show significant promise against potential bioweapon toxins
2. Compound eyes, evolutionary ties
3. Compounds in cranberry juice show promise as alternatives to antibiotics
4. Compound in wine reduces levels of Alzheimers disease-causing peptides
5. Compound reveals new link between signaling protein and cell migration
6. Compound from Chinese medicine shows promise in head and neck cancer
7. Animal study: Compounds in cranberries may have heart-healthy effects
8. Compound from Chinese medicine shows promise in head and neck cancer, U-M study finds
9. Compounds in plastic packaging act as environmental estrogens altering breast genes
10. Compound from rare plant shows promise in treating breast cancer
11. AVN944 inhibits IMPDH and induces apoptosis-related biomarkers in patients with hematologic cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
Breaking Biology News(10 mins):
(Date:7/24/2017)... ... July 24, 2017 , ... Charm Sciences, Inc. is pleased to announce the ... on Interstate Milk Shipments (NCIMS) Laboratory Committee and Appendix N Committee as a drug ... 2017. , The NCIMS voted at its annual meeting in April, 2015 to establish ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... of leading radiology and imaging centers around the U.S. that offer MR Elastography ... accurate alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017 /PRNewswire/ ... , a personalized genetic evaluations company, today announced ... their partnership investigating a genetic mutation implicated in ... extend the partnership for a second case involving ... year, the KCNQ2 Cure Alliance and Pairnomix entered ...
(Date:7/18/2017)... ... July 18, 2017 , ... Genedata, a leading provider ... and technology company, has implemented Genedata Biologics ™ to scale-up their bispecific ... Immunology, and Neurodegenerative Diseases. , The need to systematically evaluate large panels of ...
Breaking Biology Technology:
Cached News: